


CELLTRION


From Pioneer to Innovator

The 42nd Annual J.P. Morgan Healthcare Conference
Jin Seok Seo, CEO



DISCLAIMER

This presentation is given in personal capacity and represents only the author's personal views. Therefore, it does not represent the policies or recommendations of companies and regulatory bodies mentioned within the contents.



CONTENTS

I. Celltrion's Journey

- Celltrion's journey
- Expanding biosimilar pipeline to help reduce healthcare spending
- Zymfentra launch in 2024: Novel drug designed to improve patients' lives

II. Reshaping of Biosimilar Industry & Celltrion's Strategy

- Biosimilar market oligopoly
- Our strategy in oligopolistic Industry - Biosimilar portfolio expansion
- Trends in biomanufacturing: Low-volume, multi-product production
- Capacity expansion in line with low-volume, multi-product production trend

III. Drug Development Trends & Celltrion's Strategy

- Trends in therapeutic modalities by indications
- Celltrion's R&D focus areas by therapeutic modality
- Short to mid-term new drug clinical trial plans


IV. Embedding AI into Celltrion's R&D

- Celltrion HI Bank

V. Conclusion

- Robust and feasible growth strategy



The background of the slide is a light blue-grey color with a faint, artistic rendering of several cells. These cells are depicted with translucent outer membranes and darker, textured internal structures, resembling biological cells or perhaps microscopic organisms. They are scattered across the frame, with some in sharp focus and others blurred, creating a sense of depth and scientific inquiry.

01

Celltrion's Journey

1 Celltrion's Journey

From the mAb Biosimilar Pioneer to an Innovator




1 Expanding Biosimilar Pipeline to Help Reduce Healthcare Spending

Projected global cumulative savings
from biosimilars
over the next **5 years**

\$ 383 bn [IQVIA]¹⁾



Target pipeline market size growth rate ²⁾



Source :

1) AITKEN, M., & KLEINROCK, M. (2023). (rep.). Global Use of Medicines 2023 . IQVIA Institute for data science. Retrieved December 11, 2023, from <https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicines-2023/iqvia-institute-global-use-of-medicines-2023-report-01-23-forweb.pdf>.

2) IQVIA

Note :

1) From 2023 to 2027, global cumulative savings from biosimilars are expected to be \$290 bn at least and \$476 bn at most, with a baseline of \$383bn(approx. KRW 490 tn)

2) Based on the combined 2022 revenues of the reference drugs to our 22 pipeline products

1 Zymfentra Launch in 2024 : Novel Drug Designed to Improve Patients' Lives




Most prescribed IBD therapeutics for **20+ years** with proven efficacy and safety profile

More stable serum concentration and **higher C_{trough} level**

Significantly reduced time of administration
60min ➔ **1min**

Launch 2024



A background image showing a microscopic view of several cells, likely cancer cells, with prominent nuclei and textured surfaces. The image is in grayscale with a light blue tint.

02


Reshaping of Biosimilar Industry & Celltrion's Strategy

2 Biosimilar Market Oligopoly




The biosimilar market concentrates to a few dominant players

2 Our Strategy in Oligopolistic Industry : Biosimilar Portfolio Expansion



2 Trends in Biomanufacturing : Low-Volume, Multi-Product Production



Note :

1) Based on a 70kg adult weight

2 Capacity Expansion in Line With Low-Volume, Multi-Product Production Trend

Drug Substance (DS)

+

Drug Product (DP) + L&P

Increase of High-Titer Products

Adoption of small- and mid-sized bioreactors



Plant 1 SUP - 1,000L X 2



Plant 3 - 7,500L X 8

Fill-Finish and L&P Bottlenecks

Expansion of In-house
F/F line

+

Strategic partnership
with CMOs



3 sites in NA / 9 sites in Europe / 3 sites in Asia

A background image showing a microscopic view of several cells, likely cancer cells, with prominent nuclei and textured surfaces. The image is in grayscale with a light blue tint.

03

Drug Development Trends & Celltrion's Strategy

3 Trends in Therapeutic Modalities by Indications

Oncology		Autoimmune Diseases	Metabolic Diseases	
Solid Tumor	Hematologic Cancer		Fatty Liver Disease	Diabetes
Antibody Drug Conjugated (ADC)   	CAR-T   	Oral Administration/ Small Molecule Entity   Lilly acquires Dice Therapeutics for \$ 2.4 Billion	Thyroid Hormone Receptor  Resmetirom VK2809 by Viking pharma (USA) TERN-501 Terns Pharma (USA)	GLP-1 Combination   NN9389 Novo Nordisk (Denmark) LY3437943 Eli Lilly (USA)
Immune Checkpoint  	Bi/Tri-specific Antibody   Multiple Myeloma Talquetamab Follicular Lymphoma Epcoritamab			
Anti-LAG-3 Relatlimab Eftilagimod alpha				

3 Celltrion's R&D Focus Areas by Therapeutic Modality

Oncology		Autoimmune Diseases	Metabolic Diseases		
	Solid Tumor	Hematologic Cancer	Fatty Liver Disease	Diabetes	
Patients' 1 st choice	Antibody Drug Conjugated (ADC) 8 target candidates preclinical Breast Cancer NSCLC Gyneological Lung Cancer Colorectal Solid Tumor IKSUDA THERAPEUTICS PINOTBIO	CAR-T YESCARTA[®] (axicabtagene ciloleucel) KYMRIAH[®] (tisagenlecleucel) Abecma[®] (idecabtagene vicleucel)	Oral Administration/ Small Molecule Entity 4 target candidates IBD RA Rani[®] THERAPEUTICS	Thyroid Hormone Receptor 1 target candidates preclinical NASH NAFLD	GLP-1 Combination 3 target candidates preclinical Diabetes Obesity
	Patients' 2 nd choice	Immune Checkpoint 5 target candidates preclinical NSCLC Kidney Cancer Cervical Cancer Gyneological GENUV YBIOLOGICS	Bi/Tri-Specific Antibody 5 target candidates preclinical NHL Multiple Myeloma abpro[®] GENUV YBIOLOGICS		


3 Short to Mid-term New Drug Clinical Trial Plans

Modality	~2025	2026	2027	No. of target candidates
ADC 	Initiation(E) : 3 target candidates	Initiation(E) : 3 target candidates		6
Bi/tri-specific antibody 	- Initiation(E) : 1 target candidate - Initiation(E) : 1 target candidate (Abpro)	Initiation(E) : 2 target candidates	Initiation(E) : 1 target candidate	5
Immune checkpoint inhibitor 	Initiation(E) : 1 target candidate	Initiation(E) : 2 target candidates		3
Orally-administered antibody 	- Under Phase I : 1 target candidate (RANI) - Initiation(E) : 1 target candidate (RANI)			2

Note :

1) (E) = Estimation

2) Schedule is subject to change depending on the circumstances

The background of the slide features a light blue, semi-transparent image of several cells, likely embryonic stem cells, showing their characteristic round shape and internal structures. A solid green vertical bar is positioned on the left side of the slide.

04


Embedding AI into Celltrion's R&D

CELLTRION Healthcare Intelligence BANK

Celltrion Data Bank



Celltrion Modeling Bank



Various Target Indications (IBD, RA, Pso, etc.)

Highly Refined Quality Database (Drug Responsiveness, Effect, Adverse Effect, etc.)

Collaboration (K-biobank, UK Biobank, Fingenn)




Data Science Laboratory

Machine + Deep Learning for AI Model Development and Validation

Biomarker Discovery

**Drug Candidate
Screening**


Precision Medicine

The background of the slide features a light blue, semi-transparent image of several cells, likely representing embryonic stem cells or similar biological structures. These cells are scattered across the right half of the slide, with some showing distinct nuclei and others appearing as smaller, more uniform spheres. A solid green vertical bar is positioned on the left side of the slide, partially overlapping the text.

05

Conclusion

5 Robust and Feasible Growth Strategy



FROM PIONEER TO INNOVATOR

Thank you

